Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
187.85
-2.46 (-1.29%)
At close: Mar 13, 2026, 4:00 PM EDT
187.10
-0.75 (-0.40%)
After-hours: Mar 13, 2026, 7:50 PM EDT
Natera Revenue
In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth. Natera had revenue of $665.50M in the quarter ending December 31, 2025, with 39.79% growth.
Revenue (ttm)
$2.31B
Revenue Growth
+35.90%
P/S Ratio
11.38
Revenue / Employee
$375,588
Employees
6,140
Market Cap
26.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.31B |
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| Agilent Technologies | 7.07B |
| Illumina | 4.34B |
| IDEXX Laboratories | 4.30B |
| Mettler-Toledo International | 4.03B |
| Exact Sciences | 3.25B |
NTRA News
- 2 days ago - Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 2 days ago - MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - PRNewsWire
- 2 days ago - Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis - Business Wire
- 3 days ago - Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 10 days ago - Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript - Seeking Alpha
- 10 days ago - Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 15 days ago - Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation - Business Wire
- 16 days ago - Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript - Seeking Alpha